Biocodex

Biocodex develops and commercializes pharmaceutical products, primarily focused on gastroenterology. The company pioneered the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®, forming the basis for many therapeutic solutions. Biocodex leverages its deep expertise in microbiology and pharmaceutical science to deliver evidence-based products addressing global digestive health needs.

Established in 1953 in France, Biocodex originated as a family-owned pharmaceutical company. Its foundational insight was the therapeutic potential of Saccharomyces boulardii CNCM I-745®. This discovery directly led to its specialization in probiotics and digestive health, setting its path as a firm committed to research in this medical field.

Biocodex serves patients worldwide, providing digestive health solutions often recommended by healthcare professionals. The company's vision focuses on improving patient well-being through innovative, natural healthcare options. It aims to broaden its product portfolio, upholding scientific rigor and global expansion to foster healthier lives across diverse markets.